BiotechTube
Biomendics

Biomendics

San Diego, United States· Est.
biomendics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioMendics is a private, pre-revenue biotech founded in 2017 and based in San Diego, CA. The company is advancing a novel platform of small molecule liquid crystal drugs, with its lead candidate in Phase II development for epidermolysis bullosa simplex (EBS). Led by founder and CEO Dr. Karen M. McGuire, BioMendics is targeting a portfolio of rare skin disorders including epidermolytic ichthyosis and pachyonychia congenita, aiming to provide the first disease-modifying treatments for these debilitating conditions.

Rare Dermatologic Disorders

Technology Platform

MTORX™ Technology: a proprietary platform for developing small molecule liquid crystal medications designed to mend blistering and fragile skin.

Opportunities

The severe unmet need in rare dermatologic disorders like EB creates a clear path for a first-in-class therapy with potential for orphan drug designation, premium pricing, and rapid adoption.
The MTORX™ platform's applicability across multiple related skin fragility disorders offers a pipeline-in-a-product opportunity, maximizing the value of the core technology.

Risk Factors

The novel liquid crystal technology is unproven in late-stage trials, carrying high clinical and regulatory risk.
As a pre-revenue, private company, BioMendics is heavily dependent on raising additional capital to fund expensive clinical development, facing significant financial and dilution risk.

Competitive Landscape

The rare dermatology space, particularly for EB, is becoming more active with recent approvals like Krystal Biotech's B-VEC. BioMendics competes with other biotechs developing gene therapies, protein therapies, and small molecules for various EB subtypes and related conditions, though its liquid crystal approach appears mechanistically distinct.

More companies in Small Molecule Drugs →More companies in United States →